Patient or KNOW Patient™
The Patient Perspective in CKD – A Case-based Approach to Improving Management and Treatment of Hyperphosphatemia

Disturbances of bone and mineral metabolism occur early and throughout the course of chronic kidney disease (CKD). Abnormalities in phosphorus metabolism, which increase with a decrease in renal function, are common in all stages of CKD. Hyperphosphatemia is associated with increased risk of morbidity, mortality, progression of CKD, and cardiovascular risk in patients with CKD.

Phosphorus homeostasis depends on a balance of absorption, release, and distribution involving the intestines, bone, intracellular space, and kidneys, which makes controlling serum phosphorus a challenge for clinicians and patients.

Current management of hyperphosphatemia may involve dietary restriction, phosphate binder use, or dialysis. Control of phosphorus through dietary restriction of protein intake is complicated by the risk of malnutrition and potential negative effects on overall survival. Choice of phosphate binders involves the selection of aluminum-based agents, calcium salts, or non-calcium-based binders, such as sevelamer, magnesium carbonate, or lanthanum carbonate. An integral member of the successful healthcare team is the involved and knowledgeable patient. Ongoing communication and education of the patient is required to generate this success.

This educational program will provide an understanding of the underlying compensatory mechanisms involved in CKD –associated hyperphosphatemia in conjunction with learning more about how and when to safely and effectively control phosphorus levels. Additionally, this activity will highlight disparities in perception between the patient and the health care team regarding medication and chronic kidney disease that present as areas of opportunity for ongoing communication and education.

Credit Hours	Credit Type
1.75	AMA PRA
1.75	CE

 

This activity is co-provided by SCEPTER™, EduPro Resources LLC, and Quintiles Medical Education.

This activity is supported by an educational grant from Shire Pharmaceuticals.